A liposomal formulation of doxorubicin, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in adult women.
(1)Chronic Lymphocytic Leukemia (CLL)
(2)Non-Hodgkin's Lymphoma (NHL).
Induction of remission and consolidation for acute promyelocytic leukemia (APL).
For the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy and in patients undergoing myeloablative therapy followed by bone marrow transplantation. For the mobilisation of peripheral blood progenitor cells (PBPC). For the treatment of persistent neutropenia in patients with advanced HIV infection.
Treatment of symptomatic anaemia associated with chronic renal failure in adult patients and treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
SYNRIBO™ (omacetaxine mepesuccinate) for Injection
For the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs). This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with SYNRIBO.